Showing 111-120 of 1560 results for "".
Keeping a Clinical Eye on Sickle Cell Retinopathy
https://reachmd.com/programs/everyday-family-medicine/keeping-clinical-eye-sickle-cell-retinopathy/7703/Dr. Jennifer Caudle welcomes Dr. Patrick Spencer, Chairman of the Department of Ophthalmology at Grandview Medical Center in Dayton, Ohio. Their discussion centers on primary care manifestations of sickle cell retinopathy, from early to late-stage presentations and the gold standard treatment approaDebunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
https://reachmd.com/programs/project-oncology/debunking-car-t-cell-myths-the-realities-of-patient-selection-safety-and-access/36483/Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew LunningDebunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
https://reachmd.com/programs/project-oncology/debunking-car-t-cell-myths-the-realities-of-patient-selection-safety-and-access/35452/Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew LunningCurative Strategies for Sickle Cell Disease: The Future of Gene Editing
https://reachmd.com/programs/project-oncology/curative-strategies-for-sickle-cell-disease-the-future-of-gene-editing/36489/With two FDA-approved gene therapies, including the first CRISPR-based treatment, curative strategies for sickle cell disease are continuing to expand the treatment landscape. However, challenges remain in optimizing safety and accessibility, particularly for patients unable to tolerate current myelImproving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
https://reachmd.com/programs/project-oncology/improving-diagnosis-of-castleman-disease-the-key-role-of-stromal-cells/26400/Discover how stromal cells can inform new diagnostic methods and therapeutic strategies for Castleman disease.Updates on Sickle Cell Disease From ASH: A Hematologist’s Perspective
https://reachmd.com/programs/ash-action-center/updates-on-sickle-cell-disease-from-ash-a-hematologists-perspective/14199/Learn more about the latest advancements in the therapeutic landscape for patients with sickle cell disease.Beyond the Data: Improving the Lives of People with Sickle Cell Disease
https://reachmd.com/programs/grand-rounds-nation/beyond-data-improving-lives-people-sickle-cell-disease/8433/Drs. Phoebe Thorpe and Kathryn Hassell discuss sickle cell disease and how far care, treatment, and patient outcomes have come in the last 40 years.Microchimerism, Lupus, and Diabetes
https://reachmd.com/programs/clinicians-roundtable/microchimerism-lupus-and-diabetes/903/While the transfer and persistence of fetal cells into the maternal circulation is counter-intuitive, an even stranger occurrence is the reverse. Dr. Nelson discusses the evidence that maternal cells are transferring into the fetus. In the case of neonatal lupus it appears that maternal stem cellsCardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
https://reachmd.com/programs/project-oncology/cardiac-complications-in-sickle-cell-disease-emerging-evidence-and-risks/35929/Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as childhood. However, despite the severity of these issues, there are currently no uniform guidelines for asymptomatic cardiac screenManaging MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
https://reachmd.com/programs/project-oncology/managing-mcl-after-btki-failure-the-expanding-role-of-car-t-cell-therapy/35456/For patients with mantle cell lymphoma (MCL) who relapse after BTK inhibitor (BTKi) therapy, treatment decisions can be complex and time sensitive. That’s why understanding how tumor biology and risk features can guide selection between immunomodulatory regimens and CAR T-cell therapy is essential.